Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on April 27, 2017, covering events occurring on April 27, 2017, and May 1, 2017. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Departure of Director: Dr. Paul Friedman resigned from the Board of Directors effective April 27, 2017. He will continue to serve as a member of the Clinical and Scientific Advisory Board.
- Election of Director: The Board unanimously voted on May 1, 2017, to elect Dr. Eric Rowinsky as a director, effective May 3, 2017.
- Committee Role: Dr. Rowinsky will serve as the chair of the nominating and corporate governance committee.
Compensation and Governance
In connection with his election, Dr. Rowinsky is eligible to receive annual cash retainer fees and an annual stock option grant under the Company's director compensation policy. He also entered into a customary indemnification agreement with the Company.
Investor Verification Checklist
- Verify the effective date of Dr. Rowinsky's directorship (May 3, 2017) and his role as chair of the nominating and corporate governance committee.
- Review the attached press release (Exhibit 99.1) for additional details on Dr. Rowinsky's background and qualifications.
- Confirm the transition of Dr. Friedman to the Clinical and Scientific Advisory Board.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.